---
title: "Roivant swings to Q3 loss as revenue drops"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275123144.md"
datetime: "2026-02-06T12:12:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275123144.md)
  - [en](https://longbridge.com/en/news/275123144.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275123144.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275123144.md) | [繁體中文](https://longbridge.com/zh-HK/news/275123144.md)


# Roivant swings to Q3 loss as revenue drops

)

Overview

-   Biopharmaceutical firm’s Q3 revenue drops to $2 mln from $9 mln yr-ago
-   Posts Q4 net loss vs profit in year-ago quarter
-   Roivant reported $4.5 bln in cash and marketable securities as of Dec 31, 2025

Outlook

-   Roivant plans Phase 3 study for brepocitinib in cutaneous sarcoidosis starting in 2026
-   Company expects topline data from brepocitinib NIU trial in second half of 2026
-   Roivant actively exploring additional indications for brepocitinib

Result Drivers

-   R&D EXPENSES - Increase in R&D expenses driven by program-specific costs and share-based compensation
-   STRONG CASH POSITION - Reported $4.5 bln in cash and marketable securities as of Dec 31, 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $2 mln

Revenue

### Q3 EPS -$0.38

Q3 Net -$313.70

Income mln

Q3 Miss -$339.15 -$306.38

Income mln mln (6

From Analysts

Operatio )

ns

### Q3 $341.15

Operatin mln

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 11 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the pharmaceuticals peer group is “buy”
-   Wall Street’s median 12-month price target for Roivant Sciences Ltd is $26.00, about 23% above its February 5 closing price of $21.14

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Roivant Sciences Ltd. (ROIV.US)](https://longbridge.com/en/quote/ROIV.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [BUZZ-Scienture rises after deals to expand reach of opioid overdose spray](https://longbridge.com/en/news/278723928.md)
- [Longeveron Closes $15 Million Initial Tranche of $30 Million Private Placement](https://longbridge.com/en/news/278780841.md)
- [MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS](https://longbridge.com/en/news/278578150.md)
- [Moleculin to Present at 38th Annual ROTH Conference | MBRX Stock News](https://longbridge.com/en/news/279438129.md)
- [Roche Shareholders Approve All Proposals At 2026 Annual Meeting](https://longbridge.com/en/news/278577046.md)